Silexion Therapeutics expands development plan for SIL204 to target KRAS-driven pancreatic cancer

From GlobeNewswire: 2025-03-28 08:30:00

Silexion Therapeutics Corp. announces an expanded development plan for its next-generation siRNA candidate, SIL204, to target KRAS-driven pancreatic cancer through systemic and intratumoral administration. Promising preclinical findings show significant tumor growth inhibition with SIL204 in orthotopic models. The company plans to conduct toxicology and pharmacodynamic studies in 2025, with potential regulatory submissions in 2025 and 2026 for clinical trials in patients with advanced KRAS-driven pancreatic cancer. The expanded development plan is supported by positive clinical and preclinical data, with plans to present at the Cancer Advocacy Group of Louisiana NeauxCancer 2025 Conference.



Read more at GlobeNewswire: Silexion Therapeutics Unveils Innovative Expanded